Xbrane Biopharma

The Board of Directors has resolved that the record date for the reverse split shall be 20 October 2025. The first day of trading in Xbrane's share after the reverse split is 17 October 2025. As of this date, the share price reflect the effect of the reverse split.

As a result of the reverse split, Xbrane's share will change ISIN code. As of 17 October 2025, the share will trade under the new ISIN code SE0026598583.

The number of shares after the reverse share split amounts to 20,605,348 (before the reverse share split a total of 2,575,668,555 shares). Each share will have a quota value of SEK 0.10 following the reverse share split.

The reverse share split will be effected automatically via Euroclear Sweden AB and shareholders do not need to take any action. If a shareholder's holding of shares does not correspond to a full number of new shares, title to the excess shares shall pass to Xbrane on the record date and excessive shares will thereafter be sold by Eminova Fondkommission AB at Xbrane's expense, whereby shareholders concerned will automatically receive their part of the sales proceeds. Payment of the sales proceeds is expected to take place around 24 October 2025.

Timeline for the reverse share split